Lupus Tumidus Without Severe or Disseminated Skin Lesions: What to Do When Hydroxychloroquine or Chloroquine Has Not Achieved Improvement

Clinical Setting

This protocol addresses lupus tumidus in the absence of severe or disseminated cutaneous lupus erythematosus (CLE) skin lesions — a presentation in which antimalarial monotherapy is the established initial approach yet may prove insufficient in some patients.

Prior Treatment — Insufficient Response

The preceding regimen consisted of hydroxychloroquine or chloroquine as systemic monotherapy. Escalation to this protocol is indicated when improvement of cutaneous lupus erythematosus skin lesions is not achieved after 16 weeks of treatment. Once that threshold is crossed, an alternative combination strategy becomes necessary.

Treatment Approach — Partial Overview

The next step adds mepacrine as part of a combination regimen with an antimalarial agent. Mepacrine is chosen for its synergistic activity alongside these drugs. The complete combination, sequencing, and all dosing parameters are defined in the full structured protocol.

Treatment Goals

Skin lesions are expected to begin improving within 3–4 weeks, with maximum therapeutic effect typically reached after 6–8 weeks.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1111/ddg.14491

In treatment refractory cases, or in cases of intolerance or retinopathy, systemic treatment with mepacrine is suggested either instead of or in combination with HCQ or CQ.

Mepacrine is usually combined with CQ/HCQ since it acts synergistically with these drugs and does not increase the risk of retinopathy.

A daily dose of 100 mg mepacrine should ideally not be exceeded, although doses of 200 mg per day may be administered for short periods of time.

Skin lesions will improve within three to four weeks; maximum effects are seen after six to eight weeks.

View source ↗